Charles Rowland

Charlie Rowland is an accomplished board member and leader in the biotechnology and pharmaceutical sectors, currently serving as Board Member and Audit Committee Chair at Generation Bio, Board Member and Compensation Committee Chair at Nabriva Therapeutics, and Board Member and Chair of the Compensation Committee at Viking Therapeutics. With extensive experience on various boards, including past roles at Orchard Therapeutics, Blueprint Medicines, and several others, Charlie has a strong focus on companies developing innovative therapies for inherited diseases, antibiotic treatments, and metabolic disorders. Charlie holds an MBA in Finance from Rutgers University and a BS in Accounting from Saint Joseph's University, contributing robust financial acumen to roles across clinical-stage and commercial companies in the healthcare industry.